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Abstract
Background: Atypical teratoid/rhabdoid tumors (AT/RTs) are highly malignant brain tumors with inactivation of the
SMARCB1 gene, which play a critical role in genomic transcriptional control. In this study, we analyzed the genomic
and transcriptomic profiles of human AT/RTs to discover new druggable targets.
Methods: Multiplanar sequencing analyses, including whole exome sequencing (WES), single nucleotide
polymorphism (SNP) arrays, array comparative genomic hybridization (aCGH), and whole transcriptome sequencing
(RNA-Seq), were performed on 4 AT/RT tissues. Validation of a druggable target was conducted using AT/RT cell
lines.
Results: WES revealed that the AT/RT genome is extremely stable except for the inactivation of SMARCB1. However,
we identified 897 significantly upregulated genes and 523 significantly downregulated genes identified using RNA-
Seq, indicating that the transcriptional profiles of the AT/RT tissues changed substantially. Gene set enrichment
assays revealed genes related to the canonical pathways of cancers, and nucleophosmin (NPM1) was the most
significantly upregulated gene in the AT/RT samples. An NPM1 inhibitor (NSC348884) effectively suppressed the
viability of 7 AT/RT cell lines. Network analyses showed that genes associated with NPM1 are mainly involved in cell
cycle regulation. Upon treatment with an NPM1 inhibitor, cell cycle arrest at G1 phase was observed in AT/RT cells.
Conclusions: We propose that NPM1 is a novel therapeutic target for AT/RTs.
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Background
Malignant rhabdoid tumor is a highly aggressive neo-
plasm of early childhood that develops in the brain, kid-
ney, and soft tissues. In particular, malignant rhabdoid
tumors arising in the brain are called atypical teratoid/
rhabdoid tumors (AT/RTs). The prognosis of an AT/RT
is quite poor, as the 3-year overall survival rate is 22%,
with an event-free survival rate of 13%. [1] Long-term
survival is attained in less than 20% of patients [1, 2]. An
improved 2-year overall survival rate of 60% or 70% has
been reported; however, potentially toxic irradiation was
applied to young infants in these studies [3, 4].
Malignant rhabdoid tumors, including AT/RTs, are char-
acterized by genetic alterations affecting the SMARCB1 (also
known as hSNF5 and INI1) locus in chromosome 22q11.2
or, rarely, the SMARCA4 locus in chromosome 19p13.2 [5].
The SMARCB1 protein is a core subunit of the switch/su-
crose non-fermentable chromatin remodeling (SWI/SNF)
complex that regulates the expression of thousands of genes
[6]. High-resolution genomic analysis and whole exome se-
quencing studies identified extremely low mutation rates for
genes other than the biallelic inactivation of SMARCB1 in
rhabdoid tumors [5, 7]. A recent study in which whole gen-
ome sequencing was undertaken for many AT/RT samples
also reported rare recurrent mutations aside from the muta-
tions in SMARCB1 [8]. Indeed, pediatric malignant rhabdoid
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tumors have the least number of somatic mutations among
diverse human cancers [9]. These studies demonstrated that
unlike other malignant cancers, the genome of the AT/RT
is extremely stable, and alterations of SMARCB1 function
must contribute to the numerous cancer hallmarks observed
in the AT/RTs. Recent studies on the transcriptome and
methylome of AT/RT have revealed that AT/RT can be di-
vided into distinct molecular subgroups [10–12]. These sub-
groups are distinguished by epigenetic differences, reflecting
the lack of driver oncogenes in AT/RT [10]. Distinct
activation patterns of enhancers also characterize the mo-
lecular subgroups [8]. The pathogenesis of AT/RT with
SMARCB1 inactivation has not been fully elucidated. In a
murine model, knockout of SMARCB1 led to rhabdoid tu-
mors in soft tissues but never in the brain [13]. Co-deletion
of SMARCB1 and TP53 in mice caused rhabdoid tumor de-
velopment in the brain reminiscent of AT/RTs [14].
However, concurrent SMARCB1 and TP53 deletions are
rarely found in human AT/RTs. To date, no oncogenic
driver mutation in a canonical pathway has been found in a
human AT/RT [15]. The absence of an oncogenic driver
mutation and a heterogeneous subclass of genomic
characteristics make it difficult to find druggable targets for
AT/RTs [8, 10, 11].
SMARCB1, along with other members in the SWI/
SNF chromatin remodeling complex, regulates gene
expression and DNA repair. The action of SMARCB1
is context-dependent and involves multiple cellular
functions, such as the cell cycle, differentiation and
cell survival [16]. At least one-third of genes in the
genome are regulated by the SWI/SNF complex [17].
Transcriptional profiling showed that CCND1 and
EZH2 overexpression may play an important role in
rhabdoid tumors [18–20]. Inhibition of EZH2 im-
paired cell growth and abrogated tumorigenesis in
mice [18, 21]. EZH2 is a component of the polycomb-
repressive complex 2 (PRC2), and increased EZH2
expression is associated with the suppression of vari-
ous genes through specific histone methylation. A re-
cent study indicated that inactivation of SMARCB1
leads to disruptions of specific nucleosome patterning
and a loss of overall nucleosome occupancy at many
promoters, generating altered genome-wide transcrip-
tional levels [22]. Therefore, despite the lack of
somatic mutations in AT/RTs other than SMARCB1
inactivation, the extent and depth of transcriptional
dysregulation are comparatively high. Among the
many deregulated genes, identification of the most ef-
fective druggable target is still indispensable.
In this study, we sought to investigate the gene expres-
sion profiles of the AT/RT tissues that have biallelic inacti-
vation of the SMARCB1 gene. From the integrated
genomic data from tumor samples of 4 AT/RT patients, we
narrowed down the candidate therapeutic targets to identify
nucleophosmin (NPM1), a multifunctional phosphoprotein
involved in ARF/p53 pathway regulation, as a novel poten-
tial therapeutic target for AT/RTs. In vitro experiments




Pairs of snap-frozen tumor tissues and matched normal
blood samples collected at the time of surgery from 4 pa-
tients who were histologically diagnosed with an AT/RT
were used for DNA and RNA extraction. All patients had
tumors in their cerebellum and were infants or of early
childhood age (3–18months). Clinical information is
summarized in Additional file 1: Table S1. Genomic DNA
was extracted using a QIAamp DNA mini kit (Qiagen,
Cat. No. 51304), and total RNA was extracted using an
RNeasy Plus Universal Mini Kit (Qiagen, Valencia, CA,
USA, Cat. No. 73404) according to the manufacturer’s
recommendations. DNA content was quantified using a
Qubit DNA quantification kit (Invitrogen, Carlsbad, CA),
and DNA integrity was assessed by gel electrophoresis.
Samples with an RNA Integrity Number (RIN) > 5 were
selected for the study. Whole exome sequencing (WES),
single nucleotide polymorphism (SNP) arrays, array
comparative genomic hybridization (aCGH), and whole
transcriptome sequencing (RNA-Seq) were performed
using these samples, except for the normal blood sample
of one patient (P2) due to poor DNA quality. Two AT/RT
tissues used for WES were available for confirmation in
qPCR in which 8 additional AT/RT tissues were utilized.
Medulloblastoma tissues (N = 5) were used for compari-
son. This study was approved by the Institutional Review
Committee of the Seoul National University Hospital, and
written informed consent was obtained from all patients
for the usage of the samples. We excluded all identifying
information of the participants from this article.
Whole exome sequencing
We used an Agilent SureSelect 50-Mb exome capture
kit (Agilent Technologies Inc., Santa Clara, CA) for exon
target enrichment. Sequencing was performed using an
Illumina HiSeq 2000 system with 100-bp paired-end
reads. Using hg19 as a reference genome, mapping and
paring were performed using the BWA algorithm. Local
realignment was performed using GATK (http://www.
broadinstitute.org/gatk/), and duplication removal was
conducted using Picard. We obtained final BAM files
with more than 150 times the depth of coverage on the
target for all samples except one matched normal blood
sample (P2) in which the DNA sample quality was too
poor to be sequenced. The details of the calling process
for single nucleotide variants (SNVs) and indels are de-
scribed in the Additional files 1 and 2. Using SnpEff
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(ver3.6, http://snpeff.sourceforge.net), we selected varia-
tions that were non-synonymous, and rarity in the gen-
eral population was defined as < 1% in the one-thousand
genome project (http://www.1000genomes.org/) [23, 24].
To call SNVs and small indels from the WES data, we
used the Unified Genotyper (GATK-Lite 2.3.9) on the
BAM files that resulted from preprocessing of the lane-
level BAM files with the protocol described in the “Best
Practice Variant Detection with GATK v4”. Among the
protocols described in that practice, we followed the
“Best: per-sample realignment with known indels then
recalibration” protocol for the tumor/normal contrastive
calling projects. To produce lane-level BAM files from
raw sequence reads, we mapped the raw sequence reads
of each lane to hg19 using the BWA algorithm. For each
variant that was called with the Unified Genotyper, we
selected tumor-specific variants with the following som-
atic variant calling protocol, which consisted of 3 steps,
as follows. 1) We separately counted the number of
high-quality reads supporting the reference allele and
the variant allele for each variant site. 2) We performed
a permutation test that was designed to determine
whether a variant allele fraction (VAF) in a tumor sam-
ple was higher than that of the normal sample. At this
step, we calculated the VAF from the read count of the
reference allele and that of the variant allele for each
sample. 3) Finally, we selected somatic variants consider-
ing the p-value from the permutation test and VAFfrac
(VAFTumor/(VAFTumor + VAFControl)) together. We used
VAFfrac to denote a ratio between a VAF of the tumor
sample and the sum of VAFs of each sample. For this
purpose, we used a volcano plot between VAFfrac and –
log_10 (p-value). During somatic variant calling, we ex-
cluded low-quality variant sites that were determined
based on the depth of high-quality reads and other prop-
erties of the variant site.
Copy number alteration analysis
For copy number alteration (CNA) analysis of the whole
exome capture sequencing, we used CONTRA (ver1.0,
http://contra-cnv.sourceforge.net/) [25]. The Agilent
SureSelect 50M bed file was used as the target region
definition file and was applied to the CNA analysis. The
final results were summarized as the exon level log2-fold
changes of read depth between the normal and tumor
samples into the gene-level log2-fold changes using an
in-house script. Loss of heterozygosity (LOH, heterozy-
gous in the normal tissue, but homozygous in the tumor
tissue) was defined using VAF values of the normal and
tumor samples.
Whole transcriptome sequencing
The 200~500 bp double-stranded cDNA fragments
were purified by agarose gel electrophoresis and
amplified using PCR to produce libraries. Raw se-
quencing reads were produced using Illumina HiSeq
2000 with 100-bp paired-end reads. After removing
poor-quality raw reads containing the adaptor se-
quence, more than 10% of unknown bases or low
quality bases, the remaining reads were aligned to
the human reference genome (hg19). Expression pro-
files were analyzed using the reads per kilobase per
million mapped reads (RPKM) values. Details of the
expression quantification process are described in
the Additional files 1 and 2.
Differentially expressed gene analysis
To perform the differentially expressed gene (DEG) ana-
lysis, we used open source RNA-Seq data of normal brains
(BrainSpan, http://www.brainspan.org) as a control. Five
age-matched cerebellar cortex RNA-Seq datasets from the
BrainSpan database were selected (Additional file 1: Table
S2). The expression quantification process we employed
was identical to that of BrainSpan. Alignment of the reads
was performed using TopHat (version 1.3.1) [26]. For the
human genome mapping, the GTF format annotation file,
Gencode version 10 (GRCh37, Ensembl 65), was addition-
ally provided to improve the mapping quality of exon-exon
junction reads. After alignment, SAMtools (http://samtools.
sourceforge.net/) and RSEQtools (https://github.com/ger-
steinlab/RSEQtools) software packages were used to
perform RPKM-based quantification as described. RPKM
values were computed using the “mrfQuantifier” program
in RSEQtools. For the gene model, the gene composite
model that is generated using the GTF format annotation
file (Gencode version 10) was used.
Differentially expressed genes were analyzed with the
DESeq package in R software (version 3.0.2; http://
www.r-project.org/) using the negative binomial test
[27]. Up- and downregulated genes were identified as
those with RPKM values > 0.5 and with p-values < 0.05.
With the use of publicly available data such as Brain-
Span, batch effects between our data and the BrainSpan
data are inevitable. However, RPKM quantification,
which normalizes raw read counts to regions within a
sample, may eliminate batch effects. Additionally, to se-
lect differentially expressed genes, we considered prior
knowledge from two whole genome expression studies
on a microarray platform after SMARCB1 inactivation
in mouse embryonic fibroblasts (MEFs) [22, 28]. These
studies suggested that mammalian SMARCB1 (or SWI/
SNF complex) may act to repress transcriptional activa-
tion rather than to activate transcriptional repression,
and the ratio of up/downregulated genes was approxi-
mately 1.5~3. DEG analysis between the 4 AT/RT
datasets and the 5 BrainSpan datasets was performed in
R with the SAMSeq (Wilcoxon rank test) and DESeq
packages (negative binomial test), respectively. The
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negative binomial test computed statistically significant
p-values for each gene in Gencode version 10 (GRCh37,
Ensembl 65).
Single nucleotide polymorphism arrays
We applied a genome-wide SNP array (Illumina
HumanOmni5-Quad BeadChip, Illumina) that covers
4,301,332 SNPs using genomic DNA samples. B
allele frequency (BAF) values computed from the
GenomeStudio software (Illumina) were exported,
and the paired parent specific circular binary seg-
mentation (PSCBS) method was used for LOH and
CNA analysis. SNP array data were further analyzed
using the ASCAT tool to estimate the tumor purity
(Additional file 2: Figure S1) [3]. The estimated
tumor purity and further results are summarized in
Additional file 1: Table S3.
Array comparative genomic hybridization
We used Agilent SurePrint G3 Human CGH Microarray
1 × 1M arrays (Agilent Technologies) for aCGH analysis
with tumor and matched normal genomic DNA samples.
Raw data were acquired and normalized (LOWESS algo-
rithm) using Feature Extraction software (v10.7, Agilent
software). The significance test for each CNV region con-
sidered the Z-statistic using DNA Analytics (ver4.0.81,
Agilent software), which sets the window size to 1M and
the Z-score threshold to 4.0.
Gene set enrichment analysis
We performed a gene set enrichment analysis (GSEA)
with the up/downregulated DEGs in the AT/RT samples
[29]. DEGs were enriched into the predefined functional
modules in GSEA (http://software.broadinstitute.org/
gsea/msigdb/index.jsp) [30]. To select the cancer-associ-
ated genes in the gene sets that were significantly
enriched, we employed the cancer class of the Genetic
Association Database (GAD, https://geneticassocia-
tiondb.nih.gov) in DAVID (https://david.ncifcrf.gov). In
addition, for the network analysis, we applied GeneMA-
NIA software (version 3.1,2,8) [31].
Cell lines and reagents
AT/RT cell lines (BT-12 and BT-16) were obtained
from Dr. Peter Houghton (Nationwide Children’s
Hospital). Primary cultured AT/RT cells were de-
rived from 8 pediatric AT/RT patients (SNUH AT/
RT 1~7, 10) as described previously [32]. The cells
were maintained in DMEM (Gibco, Waltham, MA,
USA) supplemented with 10% fetal bovine serum
(FBS) (Gibco), penicillin (100 U/mL), and strepto-
mycin (100 mg/mL) (Invitrogen, Waltham, MA, USA)
in a humidified incubator at 37 °C and 5% CO2.
Cell viability analysis
Cell viability was determined using the EZ-Cytox kit
(iTSBiO, Seoul, Korea) according to the manufacturer’s
protocol. The cells were seeded overnight at a density of
4000 cells per well in 96-well plates. Then, the cells were
treated with an NPM1 inhibitor (NSC348884, Santa
Cruz Biotechnology, Dallas, Texas) at various concentra-
tions for 1, 2 and 3 days. The viability of DMSO-treated
cells (negative control: NC) was regarded as 100%.
Values of the 50% inhibitory concentration (IC50) were
determined using sigmoidal dose-response (variable
slope) statistics and normalized in GraphPad Prism. The
cells were treated with an IC50 dose of the NPM1 inhibi-
tor for further studies. The relative cell viability (%) was
calculated using the equation ODT/ODC × 100%, where
ODT represents the absorbance of the treatment group
and ODC represents the absorbance of the control
group, as reported previously [33].
Cell proliferation assay
The effects on cell proliferation were confirmed using the
Roche Colorimetric Assay kit 1 (BrdU labeling and detec-
tion kit III; Roche Diagnostics GmbH, Germany) according
to the manufacturer’s instructions. The absorbance of the
samples against a background control was measured using
a Microplate Reader (Molecular Devices, Sunnyvale, CA) at
a wavelength of 575 nm for BrdU.
Western blot analysis
Cells were harvested after drug treatment. After isolation
of total proteins, the protein concentration was deter-
mined. Western blot analysis was performed as de-
scribed previously [32]. Anti-NPM1 (1:1000; Abcam)
and anti-β-actin (1:5000; Sigma-Aldrich, St. Louis, MO)
antibodies were used. For native PAGE, cell lysate was
not heat denatured, and a Native PAGE Novex Bis-Tris
gel system was used (Life Technologies) according to the
manufacturer’s protocol.
NPM1 knockdown with siRNAs
NPM1 small interfering RNA (siRNA) and negative con-
trol siRNA were purchased from Bioneer (Daejeon, South
Korea). The sequences of the NPM1 siRNAs were as fol-
lows: NPM1 siRNA-1 5′-GAAGCAGAGGCAAUGAAU
UACGA-3′ (sense), 5′-CUCCGUAAUUCAUUGCCU
CUGCUUCAA-3′ (antisense); NPM1 siRNA-2 5′-
AGGUGGUAGCAAGGUUCCA-3′ (sense), 5′-UGGAAC
CUUGCACCACCU-3′ (antisense); NPM1 siRNA-3 5′-
GAAAAUGAGCACCAGUUAU-3′ (sense), 3′-AUAACU
GGUGCUCAUUUUC-3′ (antisense). siRNA-mediated in-
hibition of NPM1 expression was performed using Lipo-
fectamine RNAiMax (Invitrogen) according to the
manufacturer’s instructions. Knockdown efficiency was
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confirmed by RT-qPCR and Western blots 48 h after
transfection with NPM1 siRNA and NC siRNA.
Real-time quantitative reverse transcription polymerase
chain reaction (RT-qPCR)
Total RNA was extracted from transfected cells
using a RNeasy Plus Kit (Qiagen, Hilden, Germany).
The real-time RT-qPCR analysis of mRNAs was per-
formed using the TaqMan gene expression assay kit
(Life Technologies) on an ABI 7000 system (Applied
Biosystems, Foster City, CA) under the conditions
specified in the ABI TaqMan assay protocol.
TaqMan probes for NPM1 and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) were used. All
reactions were repeated in triplicate, and the com-
parative threshold cycle (ΔCt) method was used to
calculate the relative gene expression. The results
were normalized to GAPDH and are presented rela-
tive to the negative control.
Cell cycle analysis
Cells were plated on 100-mm plates and treated with IC50
values of the indicated chemicals. After NPM1 inhibitor
treatment at the given concentrations, cells were fixed using
ice-cold 70% ethanol, washed with 1x PBS and then sus-
pended in propidium iodide (10 μg/ml) and ribonuclease A
(0.1%). Cells were incubated for 30min in the dark at room
temperature. Propidium fluorescence was quantified after
laser excitation of the fluorescent dye by FACS (BD
Biosciences, San Jose, CA) with a cell count of 10,000 cells
per sample. Finally, the DNA content of the cells in differ-
ent phases of the cell cycle was determined using CellQuest
Software (BD Biosciences, San Jose, CA).
Data availability statement
WES and RNA-seq data are available at this link: https://
www.ncbi.nlm.nih.gov/Traces/study/?acc=SRP159412.
Results
Biallelic inactivation of SMARCB1 is the only recurrent
genomic alteration in AT/RTs
Analysis of WES, SNP arrays, and aCGH revealed
extremely low mutation frequencies overall in AT/
RT samples, which harbored a total of only 23 som-
atic mutations in all patients (Additional file 1: Table
S4). Among these few genomic alterations, biallelic
inactivation of SMARCB1 was the only consistent
somatic alteration in the samples (Fig. 1). Various
mechanisms of SMARCB1 inactivation, such as
homozygous deletion, heterozygous deletion with or
without somatic mutation, and copy-neutral loss of
heterozygosity (LOH), were observed (Table 1).
Consistent with these genetic alterations, the expres-
sion levels of SMARCB1 analyzed by RNA-Seq were
significantly downregulated in all cases compared
with controls (Fig. 1).
Fig. 1 Biallelic inactivation and expression changes of SMARCB1. a Copy number changes in SMARCB1 exons on chromosome 22 of 4 AT/RT
samples in whole exome capture sequencing. All 4 tumor samples showed loss of heterozygosity (heterozygous in the normal tissue but
homozygous in the tumor tissue) based on variant allele fraction values. b Expression differences between the AT/RT samples and the control
samples analyzed in whole transcriptome sequencing (p-value = 2.69E-05). Normalized reads per kilobase per million mapped reads (RPKM) values
revealed a significant decrease in AT/RT samples compared with normal brain samples
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Inactivation of SMARCB1 results in remarkably altered
expression of known cancer-associated genes
To screen the common transcriptional cascade genes af-
fected by SMARCB1 mutation, we investigated DEGs be-
tween AT/RT samples and controls using the SAMSeq
method in the SAMR package (R library) with the RNA-
Seq data. Overall, changes in gene expression were rela-
tively modest, and most genes had similar expression
levels (RPKM fold change (FC) between 0.5 and 2) in
AT/RT and control samples. However, a subset of genes
displayed remarkably altered expression (Fig. 2), with
897 significantly upregulated genes (Additional file 1:
Table S5; log2(FC) > 1, p < 0.05, negative binomial test)
and 523 significantly downregulated genes (Additional
file 1: Table S6; log2(FC) < − 1, p < 0.001, negative bino-
mial test) in the AT/RT samples.
Using these DEGs, we performed GSEA to identify the
key oncological effectors of AT/RTs. Ten gene sets each
were significantly enriched within the ‘Canonical path-
way’ and ‘Cancer gene neighbor’ categories (Fig. 3 and
Additional file 1: Table S7). The list of genes with their
gene sets of enrichment are summarized by an overlap
matrix (Additional file 1: Table S8). Among the 261
genes annotated in GSEA, a total of 88 genes were also
Table 1 Genetic alterations of SMARCB1 in the AT/RT samples
Patient Copy number alteration Somatic mutation (type) aRelative expression level
P1 Heterozygous deletion c.811G > T
(stop codon, homozygote)
−3.76
P2 Homozygous deletion Not available −3.42
P3 Copy neutral c.118C > T
(stop codon, homozygote)
−2.22
P4 Heterozygous deletion c.93 + 2 T > C
(splice donor, heterozygote)
−2.51
alog2-fold change of RPKM (sample to control)
Fig. 2 Heatmap showing differentially expressed genes (DEGs) in the AT/RT samples compared with the control samples. A total of 897
significantly upregulated genes (log2(FC) > 1, p < 0.05, negative binomial test) and 523 significantly downregulated genes (log2(FC) < − 1, p <
0.001, negative binomial test) in the AT/RT samples are displayed. The details of the genes are listed in Additional file 1: Table S5 and S6
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commonly annotated to the cancer class of the GAD,
and NPM1 was the most significant gene that was up-
regulated in AT/RTs (Additional file 1: Table S9). Rela-
tively elevated NPM1 mRNA expression in AT/RT was
also confirmed by qPCR compared with medulloblasto-
mas and normal brain tissues, including the cerebellum
(Additional file 2: Figure S2).
NPM1 is a potential therapeutic target in AT/RT
To verify whether the inactivation of NPM1 has a potential
therapeutic effect in AT/RTs, in vitro experiments using
NSC348884, a small molecule inhibitor that could disrupt
NPM1 oligomerization, were performed. Cell viability and
proliferation were examined in 7 AT/RT cell lines after
NPM1 inhibition. Anti-NPM1 treatment effectively sup-
pressed cell viability in all 7 tested cell lines (Fig. 4a). The
half maximal inhibitory concentration (IC50) ranged from
4.8 to 9.1 μM: IC50 values in each cell line were 6.046 ±
0.374 μM (SNUH.AT/RT-1), 5.047 ± 0.257 μM (SNHU.AT/
RT-2), 7.637 ± 0.050 μM (SNUH.AT/RT-3), 7.093 ±
0.373 μM (SNUH.AT/RT-4), 9.143 ± 0.1224 (SNUH.AT/
RT-5), 4.822 ± 0.754 μM (BT-12), and 6.076 ± 0.185 μM
(BT-16). In the BrdU labeling assay, cell proliferation was
also suppressed by NSC348884 at 10 μM in 72 h (Fig. 4b).
Western blot analysis showed that NPM1 protein expres-
sion was suppressed at IC50 doses of NSC348884 for each
cell line (Fig. 4c). Knockdown of NPM1 with siRNAs re-
duced the viability of multiple AT/RT cell lines, replicating
the effect of the NPM1 inhibitor (Additional file 2: Figure
S3). These results suggest that transient depletion of NPM1
may affect the survival rate of AT/RT cells. Taken together,
these results indicate that NPM1 is a potential target for
the anticancer treatment of AT/RTs.
Mechanism of the anticancer effect of NPM1 inhibition in
AT/RTs
For deeper insight into the anticancer mechanism of
NPM1 inhibition in AT/RTs, we entered the identified
88 cancer-associated genes that were deregulated in
AT/RT samples into GeneMANIA software (version
3.1.2.8) for network analysis. The network was
constructed using coexpression, colocalization, genetic
Fig. 3 Gene sets significantly enriched by differentially expressed genes in the AT/RT samples after gene set enrichment analysis (GSEA). Ten
gene sets each were significantly enriched within the ‘Canonical pathway’ and ‘Cancer gene neighbor’ categories. Genes that are associated with
cancer (based on the Genetic Association Database (GAD, https://geneticassociationdb.nih.gov/)) are mapped with gene sets by color code.
Among the 261 genes annotated in GSEA, a total of 88 genes were also commonly annotated to the cancer class of the GAD. NPM1 was the
most significant gene that was upregulated in AT/RTs and was found to be associated with the cell cycle in the canonical pathway
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interaction, pathway, physical interaction, and shared
protein domain relationships. Then, we selected 16
genes that were closely associated with NPM1 (AURKB,
CCNB2, CDC20, CDK2, CDK7, CDKN1A, CDT1,
CENPF, HDAC1, KIF2C, MCM3, MYBL2, MYC,
PTTG1, TOP2A, and TP53). Pathway analysis using
these selected genes, including NPM1, showed that
most of them mapped to cell cycle-related pathways
(Fig. 5). Therefore, we predicted that the anticancer ef-
fect of NPM1 inhibition in AT/RTs is mediated
through the interruption of deregulated cell cycle pro-
cesses. We validated the effect of NPM1 inhibition on
the cell cycle in vitro using 4 AT/RT cell lines. G1 ar-
rest was observed after NPM1 inhibitor treatment in 3
of the 4 cell lines tested (Additional file 2: Figure S4).
One cell line, BT-12, showed G2 arrest after NPM1 in-
hibition. In all cell lines, there was a marked increase in
sub-G1 fractions, indicating that apoptosis also plays a
role in addition to the cell cycle effects of the NPM1
inhibitor.
Discussion
Genetic alterations in subunits of the SWI/SNF complex
are quite common and occur in up to 20% of all human
cancers [34, 35]. According to accumulating evidence,
biallelic inactivation of the SMARCB1 gene has repeatedly
been found to be the almost sole driving genetic alteration
in AT/RTs [5, 7, 8, 36]. A variety of mechanisms, such as
deletions, mutations, and loss of heterozygosity, are
responsible for SMARCB1 inactivation in AT/RTs [37].
To further elucidate the genome biology of AT/RTs, we
produced a multiplanar genome dataset for 4 AT/RT sam-
ples that consisted of WES, RNA-Seq, SNP array, and
aCGH analyses.
Fig. 4 The effects of NSC348884 on multiple AT/RT cell lines. a A significant decrease in cell viability was observed at 48 h in all 7 AT/RT cell lines
tested. The half maximal inhibitory concentration (IC50) ranges from 4.8 to 9.1 μM. b In the BrdU labeling assay, cell proliferation was also
suppressed by NSC348884 at 10 μM in 72 h. c Western blot shows that NPM1 protein expression is effectively suppressed at IC50 doses of
NSC348884 for each cell line. Cropped gel images are displayed for clarification
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Consistent with previous reports, the biallelic inactivation
of SMACB1 was the only recurrent mutation identified in
our study. We also did not find any other driver alterations
in other kinds of genomic analyses, such as RNA fusion.
The virtual absence of a driver oncogene in AT/RTs has
been a hurdle for researchers seeking druggable targets of
the disease. Recent panoramic genomic analysis of 192 AT/
RTs showed that AT/RTs can be assigned to one of three
subgroups with largely homogeneous genomes: AT/RT-
TYR, AT/RT-SHH and AT/RT-MYC [8]. Although few
differences were found between subgroups at the genetic
level, the subgroups were classified by the enrichment of
transcription factors and their regulatory circuits, which
may be targets for therapy [8]. Moreover, analysis of gen-
ome-wide methylation patterns revealed substantial DNA
hypermethylation among the AT/RT-TYR and AT/RT-
SHH subtypes but not the AT/RT-MYC subgroup, which
might guide the optimal treatment of patients with AT/RTs
[8]. As previously reported [8], overexpression of EZH2, a
component of the PRC2 complex, was observed in all AT/
RTs regardless of subgroup in this study (mean log2(FC) =
2.23, p = 0.03, Additional file 1: Table S5). Based on the
relative expression ratio of subgroup-specific signature
genes compared with EZH2 in individual patient samples,
the patient samples in this study could be classified into the
previously proposed subgroups: AT/RT-TYR for P2 and
P4, AT/RT-SHH for P1, and AT/RT-MYC for P3 (Add-
itional file 2: Figure S5). [8] If we apply the other molecular
subgroup classification proposed by Torchia et al. to the
present samples, P1 was close to group 1, while the others
were compatible with group 2 (Additional file 2: Figure S6)
[11]. Efforts have been focusing on epigenetic changes in
AT/RTs and rhabdoid tumors since it was discovered that
SWI/SNF acts antagonistically toward PRC2 [38] and
showed impacts on the further subclassification of AT/RTs
[10]. Inhibition of EZH2, a component of PRC2, dramatic-
ally suppressed AT/RT cells in vitro and in vivo [18, 21].
However, their clinical application for anticancer therapy
has yet to be studied.
Among the approaches targeting various kinds of
genetic changes, cell cycle regulators are potential
therapeutic targets of interest [37]. A previous study
found that SMARCB1-deficient mouse embryonic fi-
broblasts showed a significant increase in apoptosis and
cell cycle arrest with upregulation of TP53 and
CDKN1A [28]. Pan-CDK inhibitors, such as flavopiri-
dol, affected cyclinD1 and inhibited rhabdoid tumor
cell growth [39]. A clinical trial of the CDK4/6 inhibitor
ribociclib for patients with rhabdoid tumors and other
solid cancers is currently under way [37]. In this study,
we identified NPM1 as a potential therapeutic target
that was universally overexpressed in AT/RT samples
and showed a significant anticancer effect in vitro. In
addition, the mechanism of its anticancer effect is pre-
dicted to be related to dysregulation of the cell cycle.
Increasing knowledge of NPM1 has revealed its multi-
functional role in cell biology, including proliferation
and growth control [40]. Scanning data from The
Cancer Genome Atlas (TCGA, https://tcga-data.nci.nih.
gov/tcga/) revealed that alterations of NPM1 in the
genome are observed in diverse types of cancers, among
which acute myeloid leukemia is the most frequently
affected (Additional file 2: Figure S7). Interestingly,
immunohistological analyses showed universal alter-
ation of NPM1 in human malignant rhabdoid tumors.
Venneti et al. reported that NPM1/phosphorylated
NPM1 were immunohistologically positive in 100%/
88% of 25 AT/RTs and in 100%/100% of 11 non-CNS
Fig. 5 The results of the pathway analysis using genes that were closely related to NPM1 from the selected cancer-associated genes within
differentially expressed genes in the AT/RT samples. All genes were annotated in cell cycle-related pathways
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malignant rhabdoid tumors [41]. Together with the re-
sults of p53 and MDM2 analysis, these findings indi-
cated the involvement of the p16INK4A and p14ARF
tumor suppressor pathways, which resulted in cell cycle
deregulation in malignant rhabdoid tumors [41]. We
also showed that many cell cycle-related gene expres-
sion levels are altered in AT/RTs (Fig. 3). Moreover,
other evidence has shown that SMARCB1 expression is
related to cell cycle regulation. Restoration of
SMARCB1 induced cellular senescence in rhabdoid
cancer cell lines [42, 43]. Betz et al. showed that re-ex-
pression of SMARCB1 in pediatric tumor cells led to
G1 arrest [44]. Therefore, cell cycle deregulation is one
of the tumorigenesis mechanisms caused by SMARCB1
inactivation involving NPM1. Reported evidence has
proposed that NPM1 is a transcriptional target of MYC
[45, 46]. As observed in our study, downregulation of
NPM1 delays cell-cycle progression and the entry of
cells into mitosis [47]. However, the detailed mechan-
ism of NPM1 as a proliferation enhancer in cancer cells
should be evaluated in future studies; several hypoth-
eses have been proposed, including that NPM1 is a pu-
tative stimulatory factor for DNA polymerase-α (DNA
Polα) or that NPM1 interacts with and inhibits p53 in
response to apoptotic stimuli [40]. Growing evidence
has shown overexpression of NPM1 in various cancers
and its correlation with poor prognosis [48–55].
In our study, NSC348884 induced G1 arrest in several
AT/RT cell lines (except for BT-12) (Additional file 2:
Figure S4). The inconsistent effects on different cell lines
may be attributed to subgroup heterogeneity of AT/RTs.
Despite the stable genomic status, transcriptome and
methylome profiling demonstrated that AT/RTs are a
heterogeneous group of tumors [8, 11]. This subgroup
difference can lead to inhomogeneous responses to tar-
get drugs. Protein expression of BT-12 showed the char-
acteristics of AT/RT-TYR, whereas BT-16 was close to
AT/RT-SHH (Additional file 2: Figure S8). Interestingly,
BT-12 was also the only cell line in which NPM1 siRNA
exerted no effect on cell viability (Additional file 2: Fig-
ure S3). The subgroup difference in response to drugs is
of interest because of the potential of tailored therapy to
each tumor subgroup. However, little is known about
the therapeutic targets of each AT/RT subgroup. Drug
screening tests on primary-cultured AT/RT cells using
different types of target agents would enhance the
understanding of AT/RT subgroups and prove useful in
future clinical trials.
Mounting evidence has shown that NPM1 is a promis-
ing therapeutic target for the treatment of solid cancers.
In addition, we propose NPM1 as a druggable target for
AT/RTs. The NPM1 inhibitor used in the present study is
NSC348884, which is the first small molecule developed
that specifically interacts with NPM1 [56]. NSC348884
induces the loss of oligomerization of NPM1 by targeting
its N-terminal domain, which causes functional impair-
ment [58]. The apoptotic effect and cell growth inhibition
caused by NSC348884 have been demonstrated previously
in diverse cancer cell lines [57–60]. Many other molecules
targeting NPM1 have also been developed for cancer
treatment [58]. Although testing multiple compounds
with diverse strategies for targeting NPM1 is needed to es-
tablish a more sophisticated protocol, NPM1 may be a
promising therapeutic target for AT/RT treatment.
Conclusion
In this study, we showed that the transcriptional profile
of AT/RT is highly deregulated despite the exceptional
stability of the genome. Therapeutic targets of AT/RTs
can be identified among the deregulated genes. We dem-
onstrated that NPM1, a cell cycle promoter, is the most
highly upregulated gene in AT/RTs. Pharmacological in-
hibition of NPM1 effectively abrogated the viability of
AT/RT cell lines through cell cycle arrest at the G1
phase. Therefore, we propose that NPM1 is a novel
therapeutic target for AT/RTs.
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